Our site uses cookies necessary for its proper functioning. To improve your experience, other cookies may be used: you can choose to disable them. This can be changed at any time via the Cookies link at the bottom of the page.

Université de Bordeaux
LabEx AMADEusCluster of Excellence
Cluster of excellence

Bioactive and biocooperative Materials

Bioactive and biocooperative Materials

Feedback loop-based individualized integrated medical systems, comprising an implanted sensor, battery, amplifier, processor, and actuator, are now in use in cardiac pacemakers and defibrillators. However, medical feedback loops, comprising for example among others miniature sensors and drug delivery systems that would individualize, and thereby improve the effectiveness and safety of drugs do not exist because these devices are limited by several crucial points:

-          the reliability of the sensing systems

-          the precision and targeting capabilities of the drug delivery systems

-           the size of the necessary power sources

-          the biocompatibility of all three aforementioned ingredients in the case of fully implantable systems

The present project wishes to address the above-mentioned crucial issues simultaneously within the Labex AMADEus, because a majority of the arising problems are closely related to the sophisticated design of adequate material properties. We therefore plan to benefit from the existing excellent know-how in the areas of biosensors, drug delivery, biofuel cells, nanostructuration and biofunctionalisation within the University of Bordeaux to tackle these challenges. The expected synergy effect arising from a close and formerly only partially existing interaction between the different well-identified scientific actors should lead to original approaches that will significantly contribute to solving some of the important problems related to more efficient, integrated and intelligent drug delivery.

The AMADEus project is directly derived from the global common challenge that has been fixed by the consortium, namely developing an autonomous, integrated and miniaturized drug delivery device.